Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia

被引:29
作者
Chen, Cunte [1 ]
Xu, Ling [1 ,2 ]
Gao, Rili [1 ]
Wang, Shunqing [3 ]
Zhang, Yuping [3 ]
Wang, Caixia [3 ]
Zeng, Chengwu [1 ]
Li, Yangqiu [1 ]
机构
[1] Jinan Univ, Sch Med, Inst Hematol, Key Lab Regenerat Med,Minist Educ, Guangzhou, Peoples R China
[2] Jinan Univ, Affiliated Hosp 1, Dept Hematol, Clin Med Postdoctoral Res Stn, Guangzhou, Peoples R China
[3] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Hematol, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
acute myeloid leukemia; BRD4; PD-1; PD-L1; prognosis;
D O I
10.3389/fphar.2020.582955
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Positive response to PD-1/PD-L1 blockades was observed in the treatment of solid tumors. However, the clinical response to PD-1/PD-L1 blockade varied in patients with acute myeloid leukemia (AML). It is thought that there are factors other than PD-1 and PD-L1 that may affect the effect of immunotherapy. This study explored the impact of transcriptome-based co-expression of bromodomain containing 4 (BRD4) and PD-1/PD-L1 on the overall survival (OS) of patients with AML, in order to understand whether BRD4 would affect the effect of PD-1/PD-L1 blockades. Bone marrow samples from 59 AML patients in our clinical center and data of 176 patients from the Cancer Genome Atlas (TCGA) database were used for OS analysis and validation. It was found that increased expression of BRD4 was associated with poor OS in AML patients. Moreover, co-expression of BRD4 with PD-1 or PD-L1 was related to poor OS. The co-expression of BRD4 and PD-L1 was better than BRD4 and PD-1 for OS prediction. Furthermore, co-expression of BRD4 and PD-L1 was positively correlated with high tumor mutation burden, which contributed to poor OS in AML patients. Additionally, the co-expression of BRD4 and PD-L1 was associated with poor OS in non-acute promyelocytic leukemia patients with intermediate/high risk or under 60 years. Our results suggest that transcriptome-based co-expression of BRD4 and PD-L1 is a predictor for poor OS in AML patients, which might provide novel insight into designing combinational targeted therapy for AML.
引用
收藏
页数:9
相关论文
共 28 条
[1]   BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer [J].
Adeegbe, Dennis O. ;
Liu, Shengwu ;
Hattersley, Maureen M. ;
Bowden, Michaela ;
Zhou, Chensheng W. ;
Li, Shuai ;
Vlahos, Raven ;
Grondine, Michael ;
Dolgalev, Igor ;
Ivanova, Elena, V ;
Quinn, Max M. ;
Gao, Peng ;
Hammerman, Peter S. ;
Bradner, James E. ;
Diehl, J. Alan ;
Rustgi, Anil K. ;
Bass, Adam J. ;
Tsirigos, Aristotelis ;
Freeman, Gordon J. ;
Chen, Huawei ;
Wong, Kwok-Kin .
CANCER IMMUNOLOGY RESEARCH, 2018, 6 (10) :1234-1245
[2]   PD-1 and PD-L1 antibodies in cancer: current status and future directions [J].
Balar, Arjun Vasant ;
Weber, Jeffrey S. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (05) :551-564
[3]   Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML) [J].
Braun, Thorsten ;
Gardin, Claude .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (07) :803-811
[4]   Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J].
Chalmers, Zachary R. ;
Connelly, Caitlin F. ;
Fabrizio, David ;
Gay, Laurie ;
Ali, Siraj M. ;
Ennis, Riley ;
Schrock, Alexa ;
Campbell, Brittany ;
Shlien, Adam ;
Chmielecki, Juliann ;
Huang, Franklin ;
He, Yuting ;
Sun, James ;
Tabori, Uri ;
Kennedy, Mark ;
Lieber, Daniel S. ;
Roels, Steven ;
White, Jared ;
Otto, Geoffrey A. ;
Ross, Jeffrey S. ;
Garraway, Levi ;
Miller, Vincent A. ;
Stephens, Phillip J. ;
Frampton, Garrett M. .
GENOME MEDICINE, 2017, 9
[5]   Expression profile analysis of prognostic long non-coding RNA in adult acute myeloid leukemia by weighted gene co-expression network analysis (WGCNA) [J].
Chen, Cun-Te ;
Wang, Pei-Pei ;
Mo, Wen-Jian ;
Zhang, Yu-Ping ;
Zhou, Wei ;
Deng, Ting-Fen ;
Zhou, Ming ;
Chen, Xiao-Wei ;
Wang, Shun-Qing ;
Wang, Cai-Xia .
JOURNAL OF CANCER, 2019, 10 (19) :4707-4718
[6]   Expression patterns of immune checkpoints in acute myeloid leukemia [J].
Chen, Cunte ;
Liang, Chaofeng ;
Wang, Shunqing ;
Chio, Chi Leong ;
Zhang, Yuping ;
Zeng, Chengwu ;
Chen, Shaohua ;
Wang, Caixia ;
Li, Yangqiu .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
[7]   Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes [J].
Daver, Naval ;
Boddu, Prajwal ;
Garcia-Manero, Guillermo ;
Yadav, Shalini Singh ;
Sharman, Padmanee ;
Allison, James ;
Kantarjian, Hagop .
LEUKEMIA, 2018, 32 (05) :1094-1105
[8]   Bromodomain 4: a cellular Swiss army knife [J].
Devaiah, Ballachanda N. ;
Gegonne, Anne ;
Singer, Dinah S. .
JOURNAL OF LEUKOCYTE BIOLOGY, 2016, 100 (04) :679-686
[9]   Cancer immunoediting: from immunosurveillance to tumor escape [J].
Dunn, GP ;
Bruce, AT ;
Ikeda, H ;
Old, LJ ;
Schreiber, RD .
NATURE IMMUNOLOGY, 2002, 3 (11) :991-998
[10]   Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells [J].
Fiskus, Warren ;
Sharma, Sunil ;
Qi, Jun ;
Valenta, John A. ;
Schaub, Leasha J. ;
Shah, Bhavin ;
Peth, Karissa ;
Portier, Bryce P. ;
Rodriguez, Melissa ;
Devaraj, Santhana G. T. ;
Zhan, Ming ;
Sheng, Jianting ;
Iyer, Swaminathan P. ;
Bradner, James E. ;
Bhalla, Kapil N. .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (05) :1142-1154